CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
Fees for codes L8701 and L8702 are effective as of April 1, 2024 BOSTON (March 1, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for […]
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
BOSTON (February 29, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024. […]
Myomo Closes $6M Registered Direct Offering
BOSTON (January 19, 2024) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing […]
Myomo Announces $6M Registered Direct Offering
BOSTON (January 17, 2024) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of […]
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
BOSTON (January 17, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023. (Read more)
Myomo Reports Q3 2023 Financial Results
Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 7, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical […]
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting
Public Meeting Scheduled for November 29, 2023 BOSTON (November 6, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) posted a proposed Medicare Durable […]
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (November 2, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that […]
Myomo to Report Third Quarter Financial Results on November 7, 2023
BOSTON (October 31, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023. Read […]
Myomo Announces Closing of $4.4 Million Public Offering
BOSTON (August 29, 2023) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced “reasonable best efforts” public offering of 7,333,334 shares of common stock (or common stock equivalents […]